Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Validation Study of the Neuro-cognitive Emotion Monitoring-Intervention (NEMO-I) Application in Adolescents

8 luglio 2026 aggiornato da: Seoul Women's University

This study aims to evaluate the validity and effectiveness of NEMO-I (Neuro-cognitive Emotion Monitoring-Intervention), a mobile application designed to help adolescents monitor and manage their cognitive and emotional functioning in everyday settings. NEMO-I delivers evidence-based psychological techniques-such as mindfulness, self-regulation training, and emotion monitoring-in a gamified format consisting of seven brief activities that users can complete at home in about 10 minutes each.

A total of 140 middle and high school students will participate. Participants will complete standardized neuropsychological and psychological assessments before and after the intervention period. During the 21-day intervention period, participants will use the NEMO-I application at home each day at their convenience (a minimum of 10 minutes per day is recommended). By comparing pre- and post-intervention assessment results, this study seeks to determine whether the application produces meaningful benefits for adolescent mental health and to establish its suitability as a digital mental health tool.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Stimato)

140

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Myeongjie Im, MA
  • Numero di telefono: +82-10-2588-0859
  • Email: imj@swu.ac.kr

Luoghi di studio

    • Seoul
      • Seoul, Seoul, Corea del Sud, 01797
        • Seoul Women's University
        • Contatto:
          • Myeongjie Im, MA
          • Numero di telefono: +82-10-2588-0859
          • Email: imj@swu.ac.kr
        • Investigatore principale:
          • Hyunjoo Song, PhD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Bambino
  • Adulto

Accetta volontari sani

Descrizione

Inclusion Criteria:

  • Middle or high school students currently enrolled in school
  • Using an Android-based smartphone
  • Voluntary agreement to participate, with consent from a legal guardian

Exclusion Criteria:

  • Borderline intellectual functioning or intellectual disability (IQ below 80)
  • Visual or hearing impairment
  • Prior diagnosis of intellectual, visual, or hearing impairment

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Terapia di supporto
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: NEMO-I Intervention Group
Participants in this single-arm study use the NEMO-I mobile application at home for 21 days, at their convenience each day (a minimum of 10 minutes per day is recommended). Cognitive and emotional outcomes are assessed before and after the intervention period.
NEMO-I is a mobile application that delivers evidence-based psychological techniques in a gamified format. It consists of seven brief activities-including facial expression imitation, singing, breathing and stretching with nature sounds, reading tips for everyday concerns, rhythm-based instrument play, room decoration, and mindfulness-each designed to be completed at home in about 10 minutes. Participants use the application daily during the 21-day intervention period, at their convenience, with a recommended minimum of 10 minutes per day.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in depressive symptoms
Lasso di tempo: Baseline (pre-intervention) and after the 21-day intervention period
Depressive symptoms are measured using the Beck Depression Inventory-II (BDI-II), a 21-item self-report questionnaire. Total scores range from 0 to 63, with higher scores indicating more severe depressive symptoms. Change is assessed by comparing pre- and post-intervention scores.
Baseline (pre-intervention) and after the 21-day intervention period
Change in inhibitory control (Color-Word Stroop Test, CWST)
Lasso di tempo: Baseline(pre-intervention) and after the 21-day intervention period
Inhibitory control is assessed using the Color-Word Stroop Test (CWST), which measures the efficiency of the frontal-lobe inhibition process. Performance is indexed by response time and error rate under the color-word interference condition. Change is assessed by comparing pre- and post-intervention performance.
Baseline(pre-intervention) and after the 21-day intervention period
Change in anxiety symptoms
Lasso di tempo: Baseline(pre-intervention) and after the 21-day intervention period
Anxiety symptoms are measured using the Beck Anxiety Inventory (BAI), a 21-item self-report questionnaire assessing the severity of anxiety-related symptoms. Higher scores indicate greater anxiety. Change is assessed by comparing pre- and post-intervention scores.
Baseline(pre-intervention) and after the 21-day intervention period
Change in neuro-cognitive and emotional function (NEMO-A)
Lasso di tempo: Baseline (pre-intervention) and after the 21-day intervention period
Neuro-cognitive and emotional function is assessed using the NEMO-A (Neuro-cognitive Emotion Monitoring-Assessment) application, a tablet-based, game-format assessment consisting of five subtasks. It measures domains including sustained attention, working memory, emotional sensitivity, emotion processing and recognition, audiovisual emotional integration, cognitive control, and executive function. Performance is indexed by accuracy and response time, and change is assessed by comparing pre- and post-intervention performance.
Baseline (pre-intervention) and after the 21-day intervention period
Change in visual attention and processing speed (Children's Color Trails Test, CCTT)
Lasso di tempo: Baseline (pre-intervention) and after the 21-day intervention period
Visual attention, psychomotor speed, sequential processing, and divided/sustained visual attention are assessed using the Children's Color Trails Test (CCTT). Performance is indexed by completion time (seconds). Change is assessed by comparing pre- and post-intervention performance.
Baseline (pre-intervention) and after the 21-day intervention period
Change in set-shifting ability (Trail Making Test-B, TMT-B)
Lasso di tempo: Baseline (pre-intervention) and after the 21-day intervention period
Set-shifting ability and cognitive flexibility are assessed using the Trail Making Test-B (TMT-B), which requires alternating between numbers and letters in sequence. Performance is indexed by completion time (seconds). Change is assessed by comparing pre- and post-intervention performance.
Baseline (pre-intervention) and after the 21-day intervention period

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in subjective stress
Lasso di tempo: Baseline (pre-intervention) and after the 21-day intervention period
Subjective stress is measured using a Visual Analog Scale (VAS), on which participants rate their current perceived stress level from 1 (no stress) to 10 (extreme stress).
Baseline (pre-intervention) and after the 21-day intervention period
Change in daily stress
Lasso di tempo: Baseline(pre-intervention) and after the 21-day intervention period
Daily stress is measured using a 26-item self-report scale assessing stress experienced in everyday domains such as parents, school, academics, peer relationships, appearance, and finances, rated on a 5-point Likert scale.
Baseline(pre-intervention) and after the 21-day intervention period
Change in alexithymia
Lasso di tempo: Baseline (pre-intervention) and after the 21-day intervention period
Difficulty identifying and describing one's own emotions is measured using the Korean version of the 20-item Toronto Alexithymia Scale (TAS-20K), rated on a 5-point Likert scale.
Baseline (pre-intervention) and after the 21-day intervention period
Change in executive function difficulties (self-report)
Lasso di tempo: Baseline (pre-intervention) and after the 21-day intervention period
Self-reported executive function difficulties are measured using the Brief Self-Report Questionnaire of Executive Function Difficulty for children and adolescents (40 items), rated on a 3-point Likert scale.
Baseline (pre-intervention) and after the 21-day intervention period
Change in peer relationship quality
Lasso di tempo: Baseline (pre-intervention) and after the 21-day intervention period
The quality of peer relationships is measured using a 13-item self-report scale rated on a 4-point Likert scale, including items reflecting conflict and negative peer interactions.
Baseline (pre-intervention) and after the 21-day intervention period
Change in problem behaviors (CBCL 6-18, parent report)
Lasso di tempo: Baseline (pre-intervention) and after the 21-day intervention period
Problem behaviors are assessed using the Child Behavior Checklist for Ages 6-18 (CBCL 6-18), completed by a parent or primary caregiver. It includes internalizing problems (e.g., anxiety, depression, somatic complaints) and externalizing problems (e.g., rule-breaking, aggressive behavior).
Baseline (pre-intervention) and after the 21-day intervention period
Change in ADHD symptoms (ARS, parent report)
Lasso di tempo: Baseline (pre-intervention) and after the 21-day intervention period
Attention-deficit/hyperactivity symptoms are assessed using the ADHD Rating Scale (ARS), an 18-item parent-report questionnaire comprising inattention and hyperactivity/impulsivity subscales.
Baseline (pre-intervention) and after the 21-day intervention period

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Hyunjoo Song, PhD, Seoul Women's University

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

10 luglio 2026

Completamento primario (Stimato)

28 febbraio 2027

Completamento dello studio (Stimato)

30 aprile 2027

Date di iscrizione allo studio

Primo inviato

2 luglio 2026

Primo inviato che soddisfa i criteri di controllo qualità

8 luglio 2026

Primo Inserito (Effettivo)

14 luglio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

14 luglio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

8 luglio 2026

Ultimo verificato

1 luglio 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • SWU-2605-004
  • RS-2022-KH126068 (Altro numero di sovvenzione/finanziamento: Korea Health Industry Development Institute (KHIDI), Ministry of Health & Welfare, Republic of Korea)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual participant data will not be shared with other researchers, as participants and their legal guardians were informed during the informed consent process that collected data would not be provided to third parties.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Adolescente - Problema emotivo

3
Sottoscrivi